title: Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?
authors.forename: Bryan P
authors.initials: BP
authors.lastname: Schneider
authors.forename: George W
authors.initials: GW
authors.lastname: Sledge
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077784:Axitinib; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000592:standards; D000077143:Docetaxel; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007191:Indazoles / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D057285:Precision Medicine; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D012107:Research Design; D043823:Taxoids / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D007093:Imidazoles; D007191:Indazoles; D009363:Neoplasm Proteins; D043823:Taxoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077143:Docetaxel; D000077784:Axitinib; D040262:Receptors, Vascular Endothelial Growth Factor